Lexicon Pharmaceuticals Inc

NASDAQ:LXRX   3:59:56 PM EDT
3.07
-0.22 (-6.56%)
Products

Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

Published: 06/29/2022 21:56 GMT
Lexicon Pharmaceuticals Inc (LXRX) - Lexicon Announces Positive Top-line Results From Phase 2 Proof-of-concept Study of Lx9211 in Painful Diabetic Neuropathy.
Lexicon Pharmaceuticals Inc - Lx9211 Achieved Primary Endpoint of Study.
Lexicon Pharmaceuticals - Patient Reported Outcomes (global Impression of Change) Were Improved in Patients Treated With Lx9211 Compared to Placebo.
Lexicon - Adverse Events Were More Frequent in Lx9211 Treatment Arms and at Higher Dose, With Most Common Being Dizziness, Headache and Nausea.
Lexicon Pharmaceuticals Inc - There Were No Drug-related Serious Adverse Events Reported in Study.